Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period to Evaluate the Efficacy and Safety of AGN-151607-DP (USAN: gemibotulinumtoxinA) for the Treatment of Upper Limb Essential Tremor in Adults

NCT07673107 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT07673107
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07673107 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period to Evaluate the Efficacy and Safety of AGN-151607-DP (USAN: gemibotulinumtoxinA) for the Treatment of Upper Limb Essential Tremor in Adults
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Recruiting
Start date
June 18, 2026
Completion date
November 30, 2028
Enrollment
94 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

upper limb essential tremor